Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: A multicentre, cross-sectional study

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 2, 2014, Pages 151-159

  Mahe E ^a   Reguiai, Z ^b   Barthelemy, H ^c   Quiles Tsimaratos, N ^d   Chaby, G ^e   Girard, C ^f   Esteve E ^g   MacCari, F ^h   Descamps, V ⁱ   Schmutz, J L ^j   Begon, E ^k   Bravard, P ^l   Maillard, H ^m   Boye T ⁿ   Beauchet, A ^o   Sigal, M L ^a  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c Centre Hospitalier d'Auxerre   (France)

^d HÔPITAL SAINT JOSEPH   (France)

^e UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^f HÔPITAL SAINT ELOI   (France)

^g CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^h SERVICE D ENDOCRINOLOGIE   (France)

ⁱ BICHAT HOSPITAL   (France)

^j CHU NANCY BRABOIS   (France)

^k Centre Hospitalier de Pontoise   (France)

^l Department of Dermatology   (France)

^m CENTRE HOSPITALIER DU MANS   (France)

ⁿ Military Teaching Hospital Sainte Anne   (France)

^o HÔPITAL AMBROISE PARÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; RISK FACTOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; CLINICAL TRIAL; DIABETES MELLITUS; DIET; DRUG EFFECTS; DYSLIPIDEMIAS; HYPERTENSION; OBESITY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SMOKING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIET; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; OBESITY; PSORIASIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SMOKING; WEIGHT GAIN;

EID: 84892565281     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12066     Document Type: Article

References (32)

1. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
2. Gelfand JM, Neimann AL, Shin D, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
3. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
4. Kaye JA, Li L, Jick SS,. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
5. Wolk K, Mallbris L, Larsson P, et al. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492-497.
6. Gottlieb AB, Dann F,. Comorbidities in patients with psoriasis. Am J Med 2009; 122: 1150.e1-1150.e9.
7. Channual J, Wu JJ, Dann FJ,. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009; 22: 61-73.
8. Gisondi P, Cotena C, Tessari G, et al. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-344.
9. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290-295.
10. Esposito M, Mazzotta A, Saraceno R, et al. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009; 22: 219-225.
11. Di Renzo LD, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther 2011; 24: 446-451.
12. Florin V, Cottencin AC, Delaporte E, et al. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol 2012; May 23. doi: 10.1111/j.1468-3083.2012.04571.x. [Epub ahead of print]
13. Forien M, Mahé E, Sin C, et al. Variation pondérale chez les patients recevant un traitement systémique pour un psoriasis. Ann Dermatol Venereol 2012; 139: 649-651.
14. Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin level in patients with Crohn's disease. J Clin Endocrinol Metab 2005; 90: 3510-3516.
15. Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis 2005; 64: 1137-1140.
16. Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008; 35: 855-861.
17. Alcorn N, Tierney A, Wu O, et al. Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1571.
18. Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006; 84: 1463-1472.
19. World Health Organization. Obesity and overweight. 2011. URL http://www.who.int/mediacentre/factsheets/fs311/en/index.html (last accessed: 25 April 2012).
20. Chen X, Xun K, Chen L, Wang Y,. TNF-alpha, a potent lipid metabolism regulator. Cell Biochem Funct 2009; 27: 407-416.
21. Cawthorn WP, Sethi JK,. TNF-alpha and adipocyte biology. FEBS Lett 2008; 582: 117-131.
22. Institut National de la Santé et de la Recherche Médicale, TNS Healthcare Sofres, Roche. Enquête épidémiologique nationale sur le surpoids et l'obésité. Obépi 2009. Neuilly-sur-Seine: Roche; 2009. URL http://www.roche.fr/gear/newcontents/ servlet/staticfilesServlet?type=data&communityId=re719001&id=static/ attachedfile/re7300002/re72700003/AttachedFile-10160.pdf (last accessed: 23 August 2012).
23. Batista ML Jr, Peres SB, McDonald ME, et al. Adipose tissue inflammation and cancer, cachexia: possible role of nuclear transcription factors. Cytokine 2012; 57: 9-16.
24. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-1101.
25. Daïen CI, Duny Y, Barnetche T, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012; 71: 862-868.
26. Bonta IL, Ben-Efraim S, Mõzes T, et al. Tumour necrosis factor in inflammation: relation to other mediators and to macrophage antitumour defence. Pharmacol Res 1991; 24: 115-130.
27. Maury E, Noël L, Detry R, et al. In vitro hyperresponsiveness to tumor necrosis factor-alpha contributes to adipokine dysregulation in omental adipocytes of obese subjects. J Clin Endocrinol Metab 2009; 94: 1393-1400.
28. Corcoran MP, Meydani M, Lichtenstein AH, et al. Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J Endocrinol 2010; 206: 217-224.
29. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-1370.
30. Bulgarelli A, Martins Dias AA, Caramelli B, et al. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol 2012; 59: 308-314.
31. Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010; 62: 3259-3264.
32. Chen DY, Chih HM, Lan JL, et al. Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment. BMC Med 2011; 9: 4.